Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Long-Term Debt Repayments (2022 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Long-Term Debt Repayments for 4 consecutive years, with $5.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Debt Repayments rose 33.33% to $5.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.2 million through Dec 2025, up 8.33% year-over-year, with the annual reading at $16.2 million for FY2025, 8.33% up from the prior year.
  • Long-Term Debt Repayments hit $5.0 million in Q4 2025 for Harmony Biosciences Holdings, up from $3.8 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $5.0 million in Q4 2025 to a low of $500000.0 in Q1 2022.
  • Historically, Long-Term Debt Repayments has averaged $2.5 million across 4 years, with a median of $3.8 million in 2023.
  • Biggest YoY gain for Long-Term Debt Repayments was 650.0% in 2023; the steepest drop was 0.0% in 2023.
  • Year by year, Long-Term Debt Repayments stood at $500000.0 in 2022, then skyrocketed by 650.0% to $3.8 million in 2023, then changed by 0.0% to $3.8 million in 2024, then skyrocketed by 33.33% to $5.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for HRMY at $5.0 million in Q4 2025, $3.8 million in Q3 2025, and $3.8 million in Q2 2025.